Analyzing Corium International (NASDAQ:CORI) and The Competition

Corium International (NASDAQ: CORI) is one of 105 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Corium International to related companies based on the strength of its risk, profitability, analyst recommendations, dividends, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and target prices for Corium International and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corium International 0 0 6 0 3.00
Corium International Competitors 987 3963 6965 189 2.53

Corium International currently has a consensus price target of $13.00, suggesting a potential downside of 3.49%. As a group, “Pharmaceuticals” companies have a potential upside of 19.95%. Given Corium International’s peers higher possible upside, analysts plainly believe Corium International has less favorable growth aspects than its peers.

Institutional and Insider Ownership

89.1% of Corium International shares are held by institutional investors. Comparatively, 43.2% of shares of all “Pharmaceuticals” companies are held by institutional investors. 46.5% of Corium International shares are held by insiders. Comparatively, 12.0% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Corium International and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Corium International $31.86 million -$47.79 million -8.07
Corium International Competitors $8.54 billion $1.11 billion 158.53

Corium International’s peers have higher revenue and earnings than Corium International. Corium International is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Corium International and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Corium International -149.99% -482.64% -62.37%
Corium International Competitors -2,399.68% -62.30% -7.88%

Risk and Volatility

Corium International has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Corium International’s peers have a beta of 0.97, indicating that their average share price is 3% less volatile than the S&P 500.

Summary

Corium International peers beat Corium International on 7 of the 13 factors compared.

About Corium International

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply